The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a ...
The US FDA has warned Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients.
A new FDA warning letter for French pharmaceutical company Sanofi cited a handful of issues at its biologics factory in ...
While Sanofi’s immunology megablockbuster Dupixent predictably dominated the company’s sales charts in 2024, a new golden ...
The FDA issued a warning letter to Sanofi regarding significant manufacturing violations at its Genzyme Corporation Facility in Framingham, Mass. The letter, dated Dec. 16, 2024, and amended Jan. 15, ...
Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
J&J JNJ announced fourth-quarter and full-year 2024 results, starting the earnings season for the drug and biotech sector.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback